Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
124.03
+19.09 (18.19%)
Aug 25, 2026, 3:40 PM EDT - Market open
Inhibrx Biosciences Employees
As of December 31, 2025, Inhibrx Biosciences had 110 total employees, including 109 full-time and 1 part-time employees. The number of employees decreased by 51 or -31.68% compared to the previous year.
Employees
110
Change (1Y)
-51
Growth (1Y)
-31.68%
Revenue / Employee
n/a
Profits / Employee
-$1,256,191
Market Cap
1.83B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 110 | -51 | -31.68% | 109 | 1 |
| Dec 31, 2024 | 161 | -11 | -6.40% | 156 | 5 |
| Mar 31, 2024 | 176 | - | - | 170 | 6 |
| Dec 31, 2023 | 172 | - | - | 166 | 6 |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 767 |
| Novavax | 749 |
| Innoviva | 159 |
| ORIC Pharmaceuticals | 111 |
| Bicara Therapeutics | 103 |
| Tyra Biosciences | 87 |
| ArriVent BioPharma | 77 |
| Apnimed | 65 |
INBX News
- 1 day ago - Inhibrx initiated with a Buy at H.C. Wainwright - TheFly
- 11 days ago - Inhibrx Reports Second Quarter 2026 Financial Results - PRNewsWire
- 12 days ago - Inhibrx Biosciences Quarterly report: Q2 2026 - Filings
- 12 days ago - Inhibrx Biosciences Earnings release: Q2 2026 - Filings
- 5 weeks ago - Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million - PRNewsWire
- 2 months ago - Inhibrx announces FDA acceptance of BLA for ozekibart - TheFly
- 2 months ago - Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma - PRNewsWire
- 3 months ago - Inhibrx price target raised to $325 from $300 at Stifel - TheFly